ArticleRadiographics : a review publication of the Radiological Society of North America, Inc2023
Article in Radiographics : a review publication of the Radiological Society of North America, Inc, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Utilization ofAdvances in radiation oncology · 2026Article
- Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.NPJ breast cancer · 2026Article
- Real-world application ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Uptake Patterns of [Cancers · 2026Article
- A case of invasive lobular carcinoma, highlighting the emerging role ofRadiology case reports · 2025Article
- The Novel Achievements in Oncological Metabolic Radio-Therapy: Isotope Technologies, Targeted Theranostics, Translational Oncology Research.Medical sciences (Basel, Switzerland) · 2025Review
- Automated Tools to Analyze FES PET: Translational Potential to Guide Therapy in Estrogen Receptor Positive Breast Cancer.Radiology. Imaging cancer · 2025Article
- Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Caveolin-1: an ambiguous entity in breast cancer.Molecular cancer · 2025Review
- ESR Essentials: staging and restaging with FDG-PET/CT in oncology-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging.European radiology · 2025Review
- Benign Enchondroma in a 40-Year-Old Female: Emphasizing the Importance of Early 18F-FES PET/CT Utilization.Case reports in radiology · 2025Article
- False-positive 16α-[European journal of nuclear medicine and molecular imaging · 2025Article
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer.Current oncology (Toronto, Ont.) · 2024Article
- Estrogen Receptor-targeted PET Imaging for Breast Cancer.Radiology · 2024Review
- Evaluation of [Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Dynamic whole-body [EJNMMI research · 2024Article
- PET/MRI and Novel Targets for Breast Cancer.Biomedicines · 2024Review
- Invited Commentary: A Recently Approved PET Imaging Agent to Guide Breast Cancer Therapy.Radiographics : a review publication of the Radiological Society of North America, Inc · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the United States, breast cancer is the second leading cause of cancer death in all women and the leading cause of cancer death in Black women. The breast cancer receptor profile, assessed with immunohistochemical staining of tissue samples, allows prediction of outcomes and direction of patient treatment. Approximately 80% of newly diagnosed breast cancers are hormone receptor (HR) positive, which is defined as estrogen receptor (ER) and/or progesterone receptor (PR) positive. Patients with ER-positive disease can be treated with therapies targeting the ER; however, the assessment of ER expression with immunohistochemical staining of biopsy specimens has several limitations including sampling error, false-negative results, challenging or inaccessible biopsy sites, and the inability to synchronously and serially assess all metastatic sites to identify spatial and/or temporal ER heterogeneity. In May 2020, after decades of research, the U.S. Food and Drug Administration approved the PET radiotracer fluorine 18 (
Indexed as
Identifiers
36821506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.